Rapid Micro Biosystems to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Rapid Micro Biosystems (NASDAQ:RPID), a life sciences technology company specializing in automation solutions for healthcare product manufacturing, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.
The presentation is scheduled for Tuesday, September 9, 2025, at 11:00 a.m. ET in New York. Investors can access the live webcast through the company's investor relations website at investors.rapidmicrobio.com, with a replay available after the event.
Rapid Micro Biosystems (NASDAQ:RPID), azienda di tecnologie per le scienze della vita specializzata in soluzioni di automazione per la produzione di prodotti sanitari, ha annunciato la sua partecipazione al H.C. Wainwright 27th Annual Global Investment Conference.
La presentazione 猫 prevista per marted矛 9 settembre 2025 alle 11:00 ET a New York. Gli investitori potranno seguire la diretta streaming tramite il sito delle relazioni con gli investitori della societ脿 all'indirizzo investors.rapidmicrobio.com; la registrazione sar脿 disponibile in replay dopo l'evento.
Rapid Micro Biosystems (NASDAQ:RPID), una empresa de tecnolog铆a en ciencias de la vida especializada en soluciones de automatizaci贸n para la fabricaci贸n de productos sanitarios, anunci贸 su participaci贸n en la H.C. Wainwright 27th Annual Global Investment Conference.
La presentaci贸n est谩 programada para el martes 9 de septiembre de 2025 a las 11:00 a. m. ET en Nueva York. Los inversores podr谩n acceder a la transmisi贸n en vivo a trav茅s del sitio web de relaciones con inversores de la compa帽铆a en investors.rapidmicrobio.com; habr谩 una repetici贸n disponible despu茅s del evento.
Rapid Micro Biosystems (NASDAQ:RPID), 鞚橂 鞝滍拡 鞝滌“毳� 鞙勴暅 鞛愲彊頇� 靻旊（靺橃潉 鞝勲鞙茧 頃橂姅 靸濍獏瓿柬暀 旮办垹 旮办梾鞚� H.C. Wainwright 27th Annual Global Investment Conference鞐� 彀戈皜頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟.
氚滍憸电� 2025雲� 9鞗� 9鞚� 頇旍殧鞚� 霃欕秬響滌鞁�(ET) 鞓れ爠 11鞁� 雺挫殨鞐愳劀 鞓堨爼霅橃柎 鞛堨姷雼堧嫟. 韴瀽鞛愲摛鞚� 須岇偓 韴瀽鞛愱磤瓿� 鞗轨偓鞚错姼 investors.rapidmicrobio.com鞚� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼毳� 鞁滌箔頃� 靾� 鞛堨溂氅�, 頄夓偓 頉� 雼れ嫓氤搓赴(replay)霃� 鞝滉车霅╇媹雼�.
Rapid Micro Biosystems (NASDAQ:RPID), une soci茅t茅 de technologie des sciences de la vie sp茅cialis茅e dans les solutions d'automatisation pour la fabrication de produits de sant茅, a annonc茅 sa participation 脿 la H.C. Wainwright 27th Annual Global Investment Conference.
La pr茅sentation est pr茅vue le mardi 9 septembre 2025 脿 11h00 (heure de l'Est) 脿 New York. Les investisseurs pourront suivre la diffusion en direct via le site des relations investisseurs de la soci茅t茅 脿 investors.rapidmicrobio.com ; un replay sera disponible apr猫s l'茅v茅nement.
Rapid Micro Biosystems (NASDAQ:RPID), ein Unternehmen der Life-Sciences-Technologie, das sich auf Automatisierungsl枚sungen f眉r die Herstellung von Gesundheitsprodukten spezialisiert hat, gab seine Teilnahme an der H.C. Wainwright 27th Annual Global Investment Conference bekannt.
Die Pr盲sentation ist geplant f眉r Dienstag, 9. September 2025, um 11:00 Uhr ET in New York. Investoren k枚nnen das Live-Webcast 眉ber die Investor-Relations-Website des Unternehmens unter investors.rapidmicrobio.com verfolgen; ein Replay wird nach der Veranstaltung verf眉gbar sein.
- None.
- None.
LEXINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the 鈥淐ompany鈥�), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the H.C.Wainwright 27th Annual Global Investment Conference in New York, NY.
The Company is scheduled to present on Tuesday, September 9, 2025, at 11:00 a.m. ET. A live webcast of the presentation will be available on the Rapid Micro Biosystems investor relations website at聽聽and can be accessed聽. The webcast will be archived and available for replay after the event.
About Rapid Micro Biosystems
Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company鈥檚 flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (鈥淢QC鈥�) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit鈥�痮r follow the Company on X (formerly known as Twitter) at鈥�痮r on鈥�.
Investor Contact: Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications [email protected] Media Contact: [email protected]
FAQ
When is Rapid Micro Biosystems (RPID) presenting at the H.C. Wainwright Conference?
How can investors watch the Rapid Micro Biosystems (RPID) H.C. Wainwright presentation?
What does Rapid Micro Biosystems (RPID) do?
Where is the H.C. Wainwright Conference with RPID being held?
